Health · 52 views
After TAVI, anticoagulants outperform antiplatelet agents at preventing clots
After transcatheter aortic valve implantation (TAVI), anticoagulation reduced imaging signs of clot formation on the new valve compared with antiplatelet therapy, without compromising safety.
AI Summary
The ACASA‑TAVI trial, presented at the ESC Congress 2026 and published in JAMA, found that after transcatheter aortic valve implantation, patients receiving anticoagulation therapy showed fewer imaging signs of clot formation on the new valve than those given antiplatelet therapy. The reduction in clot markers occurred without a compromise in safety outcomes. This result highlights a potential advantage of anticoagulants over antiplatelet agents in the post‑TAVI setting.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Patient-centered financial navigation assistance helps reduce financial toxicity among cancer patientsContinue reading
- Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar rangeContinue reading
- Wearing headphones during surgery may reduce nausea and vomiting afterwardContinue reading
- Adult ADHD; Encouraging Advance Care Planning; Hospital Closures in the U.S.Continue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow